Preclinical studies of chiauranib show it inhibits transformed follicular lymphoma through the vegfr2/erk/stat3 signaling pathway

HIGHLIGHTS

• who: Yuanfang Tang et al. from the Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China have published the article: Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway, in the Journal: Pharmaceuticals 2023, 16, x FOR PEER REVIEW of 22/Dec/2022
• what: Lymphoma (t-FL) for which there is no efficient treatment strategy has a rapid progression treatment resistance and poor prognosis which are the main reasons for FL treatment failure.
•  

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.